177 related articles for article (PubMed ID: 20524299)
1. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
[No Abstract] [Full Text] [Related]
2. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Al Meshari K
Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
[No Abstract] [Full Text] [Related]
3. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
[No Abstract] [Full Text] [Related]
4. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib rescue in refractory acute humoral rejection--report of a case.
Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
[No Abstract] [Full Text] [Related]
6. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
7. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
[No Abstract] [Full Text] [Related]
9. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2009; ():455-9. PubMed ID: 20524314
[No Abstract] [Full Text] [Related]
10. Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
Manitpisitkul W; Wilson N; Cooper M; Gurk-Turner C; Hurley H; Rasetto F; KuKuruga D; Barth RN; Philosophe B
Clin Transpl; 2009; ():461-3. PubMed ID: 20524315
[No Abstract] [Full Text] [Related]
11. A summary of bortezomib use in transplantation across 29 centers.
Everly MJ
Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
Island ER; Gonzalez-Pinto IM; Tsai HL; Ruiz P; Tryphonopoulos P; Gonzalez ML; Solano JP; Rossique M; Selvaggi G; Tekin A; Smith LJ; Tzakis AG
Clin Transpl; 2009; ():465-9. PubMed ID: 20524316
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports.
Wong W; Lee RA; Saidman SL; Smith RN; Zorn E
Clin Transpl; 2009; ():401-5. PubMed ID: 20524305
[TBL] [Abstract][Full Text] [Related]
15. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
16. Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.
Ryckewaert A; Allain-Launay E; Moreau A; Blancho G; Cesbron A; Blin N; Roussey G
Pediatr Transplant; 2013 Sep; 17(6):E131-6. PubMed ID: 23834525
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
18. Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.
Patel JK; Everly MJ; Kittleson M; Kobashigawa JA
Clin Transpl; 2009; ():347-9. PubMed ID: 20524297
[No Abstract] [Full Text] [Related]
19. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]